ImmunityBio (NASDAQ: IBRX) stock gained after the United Arab Emirates granted marketing authorization for its drug, ANKTIVA, for the treatment of both bladder and lung cancer.
The European Commission has announced a plan to fund seven large-scale AI computing facilities with €10 billion, aiming to attract a further €20 billion in private investment to bolster the bloc's technological competitiveness.
The pharmaceutical giant lifted its 2026 revenue and profit guidance after second-quarter results topped Wall Street estimates, propelled by robust sales from blood thinner Eliquis and its newer portfolio of medicines.
Shares of the casino operator fell in pre-market trading after Argus Research cut its rating to Hold, adding to investor concerns following a recent quarterly earnings miss.
The industrial manufacturer's stock declined following its second-quarter earnings release in a 'sell the news' event, as the report did not appear to justify a recent rally that had pushed shares near a 52-week high.
Shares of the Invisalign maker fell after the company issued a third-quarter revenue outlook that missed analyst expectations, overshadowing a solid second-quarter performance and an expanded share buyback plan.
The Bank of England kept its key interest rate unchanged at 3.75%, but a split vote and hawkish forward guidance indicate a readiness to raise rates to combat persistent inflation risks.
Shares of the vertical software and insurance firm jumped after it reported second-quarter results that significantly exceeded analyst estimates, raised its 2026 forecast, and disclosed a new stake by BlackRock.
The Marlboro maker fell short of second-quarter profit forecasts as consumers, pressured by economic uncertainty, abandoned premium cigarettes for cheaper alternatives. The shift also impacted sales volumes for its key On! nicotine pouch brand.
